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 Abstract 
 Frontotemporal lobar degeneration (FTLD) is a heterogene-
ous group of syndromes with different symptoms. Frontotem-
poral lobar degeneration is mostly used as a clinical umbrella 
term for different diseases. In some clinical subtypes of the 
FTLD spectrum, a close correlation with underlying pathol-
ogy can be found. Neuroimaging techniques, such as mag-
netic resonance imaging and position emission tomography 
help to detect neuroanatomical lesions and therefore obtain 
relevance for in vivo prediction of neurodegeneration. How-
ever, there is still a lack of neurochemical biomarkers help-
ing to differentiate between underlying histopathologies. 
The following review gives an overview about present neu-
rochemical biomarker studies and perspective approaches in 
the diagnosis of FTLD. 
 Keywords:  cerebrospinal fl uid (CSF);  C9ORF72;  frontotem-
poral lobar degeneration;  neurochemistry;  primary progres-
sive aphasia;  progranulin;  TDP-43 .
 Zusammenfassung 
 Die frontotemporale Lob ä rdegeneration umfasst eine 
heterogene Gruppe von Syndromen, deren klinische 
Symptomatik sehr vielf ä ltig ist. Die frontotemporale 
Lobärdegeneration ein  Ü berbegriff f ü r unterschiedliche 
 *Correspondence: Prof. Dr. Markus Otto, Department of Neurology, 
University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany 
Tel.:  + 49-731-500-63010
Fax:  + 49-731-500-63012
 E-Mail :  markus.otto@uni-ulm.de 
Erkrankungen. F ü r einige dieser klinischen Untergruppen 
im FTLD-Spektrum kann ein enger Zusammenhang mit der 
zugrundeliegenden Neuropathologie gefunden werden. Mit 
Hilfe von Bildgebungstechniken, wie der Kernspintomo-
graphie (MRT) und der Positronen-Emissions-Tomographie 
(PET), k ö nnen neuroanatomische Ver ä nderungen festgestellt 
werden und sind damit von hoher Relevanz neurodegenerative 
Ver ä nderungen zu Lebzeiten vorherzusagen. Jedoch gibt es 
immer noch keine neurochemischen Biomarker, mit deren 
Hilfe man einzelne histopathologische Subtypen unterscheiden 
kann. Die folgende  Ü bersicht stellt die derzeitigen Biomarker-
Studien und k ü nftige Ans ä tze zur Diagnosestellung der 
frontotemporalen Lob ä rdegeneration dar. 
 Schl ü sselw ö rter:  C9ORF72;  frontotemporale 
Lob ä rdegeneration;  Liquor;  Marker;  Neurochemie;  prim ä r 
progrediente Aphasie;  Progranulin;  TDP-43. 
 Introduction 
 Frontotemporal dementia (FTD) comprises the second most 
common type of early onset dementia accounting for 5 – 10 % 
of cases of dementia. FTD, however, as a diagnostic spec-
trum refers to subgroups of clinical syndromes with differ-
ent symptoms. There is some consensus that FTD is used 
as a clinical umbrella term for clinical subtypes and fronto-
temporal lobar degeneration (FTLD) is used for the neuro-
pathological description. Recently, the consensus criteria for 
a behavioral variant frontotemporal dementia (bvFTD) and 
for a language variant known as primary progressive aphasia 
(PPA) were revised  [1, 2] . The spectrum of FTD also includes 
atypical parkinsonian syndromes: corticobasal syndrome 
(CBS) and progressive supranuclear palsy (PSP). Addi-
tionally, amyotrophic lateral sclerosis (ALS) patients who 
develop a bvFTD in the course of the disease are included 
in this spectrum (ALS-FTD). Approximately 10 % of patients 
with FTD develop ALS and patients with ALS show behavio-
ral and language changes (FTLD-ALS)  [3 – 6] . 
 On the basis of neuropathological fi ndings, FTD is associ-
ated with FTLD and abnormal protein aggregates in almost 
all cases. Historically, FTLD patients were subclassifi ed as 
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tau-positive cases (FTLD-tau) and those with tau-negative, 
ubiquitin-positive inclusions (FTLD-U). In most FTLD-U 
cases, the ubiquitinated protein is TAR DNA-binding pro-
tein-43 (TDP-43)  [7] and the term FTLD-TDP was recently 
introduced for this subgroup  [8] , whereas in approximately 
10 % of FTLD-U cases FUS (fused in sarcoma) protein 
pathology could be found  [9, 10] , and the term FTLD-FUS 
was introduced for this FTLD subtype  [11] . TDP-43 and FUS 
pathology are also found in patients with ALS. Recently, as 
a specifi c feature of FTLD-FUS, but not of ALS-FUS, the 
co-accumulation of all members of the FET protein family 
that also includes Ewing ' s sarcoma protein (EWS), TATA-
binding protein-associated factor 15 (TAF15) and the  Droso-
phila ortholog Cabeza, was recently described by Neumann 
et al. and proposed to be designated as FTLD-FET cases 
 [12] . In a small subset of cases, inclusions are positive 
for proteins of the ubiquitin proteasome system, but nega-
tive for tau protein, TDP-43 and FUS (FTLD-UPS), sug-
gesting that additional protein abnormalities will be found 
in FTLD  [11] . The link between the protein tau and FTLD 
was further strengthened by the discovery that mutations in 
the microtubule-associated protein tau gene ( MAPT ) cause 
familial FTLD-tau  [13] . Later, other mutations, e.g., in the 
progranulin gene ( GRN ) were discovered in the majority of 
familial FTLD-TDP cases  [14] . Rare forms of FTLD-TDP 
are associated with mutations in the  TAR-DNA- binding pro-
tein  [15 – 17] or valosin-containing protein gene ( VCP ). Most 
recently a hexanucleotide repeat expansion in C9ORF72 was 
described to be one cause of chromosome 9p21-linked ALS-
FTD  [18, 19] . In addition, mutations in the charged multive-
sicular body protein 2B gene ( CHMP2B ) are associated with 
FTLD-UPS  [20, 21] . 
 As shown in Figure  1 for some clinical subtypes of the 
FTLD spectrum, a close correlation with underlying pathol-
ogy can be found. PSP with predominantly parkinsonian 
symptoms is positive for tau protein inclusions  [22, 23] , other 
FTLD variants, such as CBS and progressive nonfl uent apha-
sia (PNFA) show tau protein and TDP-43 pathology  [24] . The 
most common clinical type bvFTD can be associated with all 
three molecular subtypes  [9, 25] , whereas the motor neuron 
disease variant is mainly associated with TDP-43 positive 
inclusions. As TDP-43 is also found in familiar and sporadic 
ALS a pathophysiological continuum of both diseases is sug-
gested  [5] . 
 Neurochemical markers are therefore needed for early and 
differential diagnosis and for clinical defi nition of molecular 
subtypes of FTLD to allow the perspective of subtype specifi c 
treatment. 
 Two research approaches can be considered for the labo-
ratory diagnosis of FTLD: (i) the direct detection of patho-
logical hallmark proteins and (ii) the detection of surrogate 
markers in biological materials that show an altered pattern 
of expression in early stages of the disease or are used in the 
differential diagnosis of other dementias and thus enable an 
exclusion diagnosis. Thus far, information on specifi c mark-
ers, such as tau protein, TDP-43 or FUS aggregates is lim-
ited or does not exist, which might also be due to the fact 
that these neuropathological hallmarks were only detected 
PSP
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 Figure 1  Clinical syndromes (top row), pathological subtypes 
(middle row), and common gene mutations (bottom row) in FTLD 
are shown. 
 Arrows represent links between clinical syndromes, genes, and 
underlying histopathology, with thicker arrows corresponding to 
stronger relationships. bvFTD, behavioral variant frontotemporal 
dementia; CBS, corticobasal syndrome; FTLD-ALS, FTLD with 
amyotrophic lateral sclerosis; FTLD-TAU, FTLD with tau-positive 
inclusions; FTLD-FUS, FTLD with fused in sarcoma (FUS)-positive 
inclusions; FTLD-TDP, FTLD with TAR DNA-binding protein 43 
(TDP-43)-positive inclusions; MAPT, microtubule-associated pro-
tein tau; PGRN, progranulin; PNFA, progressive nonfl uent aphasia; 
PSP, progressive supranuclear palsy; SD, semantic dementia  [3] . 
Reproduced by kind permission from Rabinovici GD and Miller BL, 
CNS Drugs 2010. Clinical, pathological and genetic spectrum of 
frontotemporal lobar degeneration (FTLD).  
recently. Thus, most of the studies have predominantly con-
centrated on evaluating biomarkers which are used for the 
differential diagnosis of FTLD vs. Alzheimer ' s disease (AD). 
 However, the combination of symptoms in FTLD can be 
highly variable and multifaceted, and for a biomarker study 
either a neuropathological verifi cation or at least highly stand-
ardized protocols for the clinical examination are necessary. 
However, ascertainment of a pathological diagnosis is seldom 
done and in the absence of reliable and valid measuring meth-
ods usually non-standardized  “ tests ” are used. This also holds 
true for magnetic resonance imaging and additional neuroim-
aging techniques. These are major drawbacks in determining 
the quality of a biomarker study for FTLD. 
 Among the studies investigating cerebrospinal fl uid (CSF) 
as a diagnostic tool, only a few comprehensively deal with 
FTLD. In several studies, FTLD patients were analyzed in 
 “ control ” groups, but because the clinical information was so 
limited these studies were not included here. 
 tau and amyloid- β in FTLD 
 For tau protein and amyloid- β mainly mild changes have 
been described (Table  1 ). Bian et al.  [29] show that tau 
protein is a potentially valuable biomarker for differenti-
ating FTLD from AD. Four histopathological tau-negative 
patients of the FTLD spectrum had signifi cantly reduced 
CSF tau levels compared with AD, whereas three of the 
FTLD-tau cases showed elevated CSF tau levels. None of 
the FTLD cases presented elevated tau/amyloid- β 1 – 42 levels. 
The ratio of tau protein and amyloid- β 1 – 42 was signifi cantly 
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 Table 1  Studies for standard CSF biomarkers: protein tau and amyloid- β in 2002 – 2011. 
Study Test persons, n Total, n Genetics Autopsy Mean value in 
FTLD vs. ND
Study groups AD FTLD ND ALS ALS + DI ALS + FTD
 [26] 74 34 40 148 ApoE- ε 4 tau  ↑ 
–  24 FTD A β -42  ↓ 
–  7 PPA
–  3 SD
 [27] 30 30 30 90 tau  ↑ 
A β -42  ↓ 
A β -38  ↓ 
A β -40  ↑ 
 [28] 39 21 30 90 1 FH A β -42  ↓ 
A β -40  ↓ 
 [29] 19 30 30 79 11 FTLD 19 FTLD tau  ↑ 
–  2 G272V –  13 tau-positive A β -42  ↑ 
–  6 P301L –  17 tau-negative
–  3 GRN
 [30] 12 13 12 3 6 46 4 FH A β -42  ↓ 
–  1 PPA
 [31] 60 55 40 155 A β -42  ↓ 
–  36 FTD tau  ↑ 
–  14 SD
–  12 PPA
 [32] 25 37 20 82 A β -42  ↓ 
–  25 FTD tau  → 
–  12 PPA
 AD, Alzheimer ' s disease; FTLD, frontotemporal lobar degeneration; ND, non-demented controls; ALS, amyotrophic lateral sclerosis; ALS + DI, 
amyotrophic lateral sclerosis with frontal disinhibition; ALS + FTD, amyotrophic lateral sclerosis with frontotemporal dementia; FTD, fronto-
temporal dementia; PPA, primary progressive aphasia; SD, semantic dementia; FH, family history. 
lower in FTLD than in AD and discriminated FTLD from 
AD with a sensitivity of 79 % and specifi city of 97 % . How-
ever, there was no discrimination between FTLD and non-
demented control groups. 
 In summary, the mean concentration for total tau protein 
and amyloid- β 1 – 42 is between the mean values of the AD 
group on the one hand and the control group (non-demented) 
on the other hand. The average value of amyloid- β 1 – 42 is 
higher in FTLD than in the respective AD group and lower 
than the non-demented group. However, in another study 
with autopsy and genetically proven FTLD the mean value of 
amyloid- β 1 – 42 was with 531 pg/mL higher compared with the 
lower mean value of 429 pg/mL in non-demented controls. 
The average value of tau protein in the respective groups 
is lower in FTLD compared with AD and higher compared 
with the control group. Within the amyloid- β peptides, the 
mean value of amyloid- β 1 – 38 in the FTLD group is 160 pg/mL, 
which is lower than in the respective AD group (217 pg/mL) 
and the control group (226 pg/mL)  [27] . Whereas one study 
shows that amyloid- β 1 – 40 is increased in the FTLD group 
and the ratio of amyloid- β 1 – 38 and amyloid- β 1 – 40 seems to 
achieve the best discrimination with a sensitivity of 87 % and 
a specifi city of 90 %  [27] , another study shows decreased 
amyloid- β 1 – 40 levels with an increased ratio of amyloid- β 1 – 42 
to amyloid- β 1 – 40 in comparison to the AD and non-demented 
control groups  [28] . 
 Other neurochemical markers for the diagnosis 
of FTLD 
 Apart from tau protein and amyloid- β 1 – 42 several other mark-
ers were investigated (Table  2 ). Galimberti et al.  [41] attracts 
attention with study groups with more than 100 patients inves-
tigated. Unfortunately, the biomarker result for MCP-1 in the 
CSF could only be evaluated in a subset of 23 FTLD patients. 
Others concentrated on the genetic contribution to the etiol-
ogy of FTLD. As mutations in the  GRN gene were identifi ed 
as a causal mechanism underlying FTLD  [14] , some stud-
ies refer to FTLD cases with a positive proven  GRN mutation 
(FTLD + GRN). It was shown that progranulin levels in plasma 
and CSF are lower in FTLD + GRN than in FTLD without  GRN 
mutation. This was also evident when FTLD + GRN patients 
were compared with controls. Unfortunately, progranulin levels 
were only tested on eight FTLD ( + ) cases. Ghidoni et al.  [38] 
established that in CSF a cut-off level of 518 pg/mL reaches a 
specifi city and sensitivity of 100 % and therefore seems to be a 
promising method of screening such cases. For plasma, the pro-
granulin protein cut-off level was 74.4 ng/mL with a specifi city 
and sensitivity of 100 % for mutation carriers among unaffected 
subjects. In FTLD values  ≤ 110.9 ng/mL give a specifi city of 
92.8 % and a sensitivity of 100 % for PGRN mutations. Finch et 
al. distinguished  GRN mutation carriers from non- GRN carriers 
at a progranulin plasma cut-off level of 112 ng/mL  [42] . 
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 Table 2  Studies for different biomarkers in CSF and plasma 2007 – 2010. 
Study Test persons, n Total, n Genetics Autopsy Biomarker
Study groups AD MCI FTLD ND DLB ALS ALS + DI ALS + FTD
 [33]   70   28   26 18 142 Neurofi laments/CSF
 [34]   85   20   32 222 Cystatin C/CSF
 [35] 102   35   85 132 TDP-43/plasma
 [36]   24   28  52 6 FTLD + 14 FTLD-TDP TDP-43/plasma
GRN 14 FTLD tau
16 AD + TDP
 [37]   12   13 15 3 9   52 TDP-43/CSF
 [38]   71 148 219 71 FTLD GRN/CSF, plasma
–  8 GRN + 
  73 ND
–  22 GRN + 
 [39]   16   12   28 Granins/CSF
 [40]   4 9   2   15 ERK1/2/CSF
 [41] 212 203 415 23 FTLD MCP-1A
– 14 TDP-43 -2518G/CSF
– 9 tau-positive
 [42]   72 219   70 361 28 GRN + GRN/plasma
–  19 ND
–  9 FTLD
 [43]   66   23   33   2 124 AgRP/CSF
 AD, Alzheimer ' s disease; MCI, mild cognitive impairment; FTLD, frontotemporal lobar degeneration; ND, non-demented controls; DLB, 
dementia with Lewy bodies; ALS, amyotrophic lateral sclerosis; ALS + DI, amyotrophic lateral sclerosis with frontal disinhibition; ALS + FTD, 
amyotrophic lateral sclerosis with frontotemporal dementia; GRN + , mutation in the progranulin gene. 
 Another study focuses on further classifi cation of patients 
with neurodegenerative diseases with a negative biomarker 
profi le for current AD markers using multi-analyte profi ling 
(MAP). MAP biomarkers combined with current AD bio-
markers achieved a sensitivity and specifi city of 92 % and 97 % 
for diagnosing AD. In a subanalysis of this study, Hu et al. 
 [43] analyzed 23 autopsy proven FTLD subtypes, including 
14 TDP-43 positive and 9 tau protein positive FTLD cases. In 
the study, amyloid- β 1 – 42 , p-tau 181 and agouti-related peptide 
(AgRP) were seen as useful classifying analytes: with AgRP 
levels elevated in a higher proportion of FTLD-TDP cases, 
compared with a small proportion of FTLD-tau cases. This 
study can be seen as a fi rst approach for the differentiation 
between the subgroups of FTLD as autopsy proven diagno-
ses are applied. As TDP-43 inclusions are found in a major 
subgroup of FTLD, it is therefore becoming an important 
biomarker to clarify pathophysiologically regulated pathways 
and to create an opportunity to develop disease-modifying 
therapies. Increased amounts of TDP-43 and phosphoryl-
ated TDP-43 plasma levels have been found in patients with 
FTLD and AD compared with controls and thereby index 
TDP-43 pathology within the brain  [35, 36] . Our studies 
focus on TDP-43 as a biological marker in CSF. As TDP-43 is 
mainly found in sporadic ALS cases and signifi cantly higher 
levels of TDP-43 are found in their CSF when compared with 
age-matched controls  [44] , we decided to investigate these 
patients in a proof-of-principle type of manner, as here the 
neuropathology can be easier predicted compared with the 
other diagnosis of the FTLD spectrum, especially the bvFTD 
cases  [37] . This included FTLD, FTLD + ALS and ALS cases. 
Here, no evidence of pathologically altered TDP-43 proteins 
in CSF could be seen. Methodological diffi culties, such as 
the heterogeneity of commercially available antibodies, anti-
body cross-reaction with IgG, and the possible dysfunction of 
the CSF-blood barrier with high TDP-43 immunoblot bands 
in plasma may account for variation in results. However, 
TDP-43 levels might aid in characterizing subgroups of 
patients across the ALS and FTLD disease spectrum. 
 In summary, sustainable success of biomarker projects 
will mainly depend on comparable protocols in either the 
preanalytical or clinical phases. This makes it necessary to 
specify and agree upon diagnostic criteria for the inclusion of 
test individuals into studies. Current contradicting results are 
most likely due to these methodical drawbacks. 
 In conclusion, the main explorative studies show that a 
relation between biomarkers and diagnostic groups cannot 
be excluded. As a minimum requirement, future studies 
with biomarkers should be based on an appropriate number 
of test individuals and clear predefi ned diagnostic criteria. 
Therefore, genetically or neuropathologically defi ned cohorts 
are mandatory. Newly set-up consortia between institutions 
specializing in the diagnostic spectrum of FTLD ( www.
ftld.de ) are very promising to build-up a crucial number of 
patients allowing in-depth research in this area. 
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